{"id":10649,"date":"2026-06-24T15:57:12","date_gmt":"2026-06-24T15:57:12","guid":{"rendered":"https:\/\/stoxpo.com\/?p=10649"},"modified":"2026-06-24T15:57:12","modified_gmt":"2026-06-24T15:57:12","slug":"viking-therapeutics-advances-pipeline-with-new-clinical-trial-launch","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/06\/24\/viking-therapeutics-advances-pipeline-with-new-clinical-trial-launch\/","title":{"rendered":"Viking Therapeutics Advances Pipeline with New Clinical Trial Launch"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Shares rise as biotech firm begins Phase 1 study of experimental therapy VK3019<\/h4>\n\n\n\n<p>Shares of Viking Therapeutics (VKTX) moved higher after the biotechnology company announced the initiation of a Phase 1 single ascending dose clinical trial for VK3019, an important step forward in the development of its experimental drug pipeline.<\/p>\n\n\n\n<p>The newly launched study is designed to evaluate the safety, tolerability, and pharmacokinetics of VK3019 in healthy volunteers. Phase 1 trials represent the first stage of human testing and are critical in determining whether a drug candidate is suitable for further clinical development.<\/p>\n\n\n\n<p>Investors reacted positively to the announcement, viewing the trial initiation as a sign of continued progress in Viking&#8217;s research and development efforts. The company has attracted significant attention in recent years for its expanding portfolio of therapies targeting metabolic and endocrine disorders.<\/p>\n\n\n\n<p>While VK3019 remains in the early stages of development, the launch of the clinical trial marks a key milestone that could pave the way for future studies and potential commercialization. As the trial advances, investors will be closely monitoring results for indications of safety and effectiveness.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares rise as biotech firm begins Phase 1 study of experimental therapy VK3019 Shares of Viking Therapeutics (VKTX) moved higher after the biotechnology company announced the initiation of a Phase 1 single ascending dose clinical trial for VK3019, an important step forward in the development of its experimental drug pipeline. The newly launched study is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1142,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[308,360],"tags":[421,416,418,417,793],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/10649"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=10649"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/10649\/revisions"}],"predecessor-version":[{"id":10650,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/10649\/revisions\/10650"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1142"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=10649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=10649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=10649"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=10649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}